Literature DB >> 6639055

The comparative kinetics of soluble and heparin-Sepharose-immobilized bovine lipoprotein lipase.

I Posner, C S Wang, W J McConathy.   

Abstract

While lipoprotein lipase (LPL) acts in vivo as an immobilized enzyme, its kinetics are commonly studied with soluble LPL (S-LPL). Hence kinetic parameters of S-LPL and heparin-Sepharose-immobilized LPL (B-LPL) were compared. A modified purification procedure for bovine milk, LPL gave a 56% yield of S-LPL, purified 7250-fold, and a specific activity of 27,000 mumol fatty acid/mg LPL/h when assayed with triolein (TG) emulsions in the presence of serum. The purified LPL also showed low but detectable esterase activity with p-nitrophenylacetate and p-nitrophenylbutyrate as substrates. Apolipoprotein C-II (C-II) had no effect on the esterase activity of LPL. Dixon plots of experiments with S-LPL indicated that heparin is a competitive inhibitor against both C-II and TG, and that the binding of either C-II or heparin to the enzyme is a mutually exclusive event. Similarly, the binding of TG and heparin to the enzyme is mutually exclusive. From the Dixon plots, the dissociation constant Ki for the LPL:heparin binary complex was determined to be 5.0 X 10(-8) M. In contrast to the heparin inhibitory effect on LPL activity against triolein, heparin had no effect on the esterase activity of LPL against p-nitrophenylacetate or p-nitrophenylbutyrate. Comparative studies with B-LPL and S-LPL, using triolein as substrate and apolipoprotein C-II or serum as activator, indicated that S-LPL has a higher apparent Km and lower apparent Vmax than B-LPL. It is concluded that most of the LPL bound to heparin-Sepharose is probably inaccessible to substrate, hence a low Vmax. However, Km (C-II) and Km (TG) were higher for B-LPL due to the competitive inhibitory effect of heparin on LPL. Consistent with these kinetic analyses and with the use of human very low density lipoproteins (VLDL) as substrate, S-LPL, even in the presence of heparin, was found to have an apparent rate of lipolysis of VLDL approximately ninefold greater than B-LPL.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639055     DOI: 10.1016/0003-9861(83)90297-7

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  C-terminal domain of apolipoprotein CII as both activator and competitive inhibitor of lipoprotein lipase.

Authors:  Q Cheng; P Blackett; K W Jackson; W J McConathy; C S Wang
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

2.  Transport of lipoprotein lipase across endothelial cells.

Authors:  U Saxena; M G Klein; I J Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. A possible pathophysiologic explanation for familial combined hyperlipidemia.

Authors:  K J Williams; K A Petrie; R W Brocia; T L Swenson
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.